Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 2
2008 1
2009 1
2012 1
2015 2
2016 4
2017 2
2018 3
2019 2
2020 2
2021 4
2022 7
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study.
Komatsu H, Matsumoto K, Morita M, Nagasawa T, Nishio H, Suzuki J, Nishio S, Kobara H, Yunokawa M, Ariyoshi K, Hirayama T, Tokunaga H, Ukita M, Yoriki K, Mori-Uchino M, Furusawa A, Togami S, Nakamura H, Ishikawa M, Satoh T. Komatsu H, et al. Among authors: nagasawa t. Cancer Med. 2024 Mar;13(5):e6968. doi: 10.1002/cam4.6968. Cancer Med. 2024. PMID: 38491829 Free PMC article.
A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system.
Chiba Y, Kagabu M, Osakabe M, Ito R, Sato S, Takatori E, Kaido Y, Nagasawa T, Shoji T, Yanagawa N, Baba T. Chiba Y, et al. Among authors: nagasawa t. Jpn J Clin Oncol. 2024 Apr 6;54(4):424-433. doi: 10.1093/jjco/hyad192. Jpn J Clin Oncol. 2024. PMID: 38251744
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
Abe M, Shoji T, Chiba Y, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Takahashi F, Aida T, Baba T. Abe M, et al. Among authors: nagasawa t. Anticancer Res. 2023 Mar;43(3):1265-1272. doi: 10.21873/anticanres.16273. Anticancer Res. 2023. PMID: 36854492
Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601.
Ito K, Nakagawa M, Shimokawa M, Hori K, Tashima L, Goto M, Yanagida S, Suzuki J, Kaya R, Kawabata A, Yamada K, Park J, Nasu H, Nishio S, Kondo E, Kaneda M, Tsubamoto H, Arakawa A, Nagasawa T, Motohashi T. Ito K, et al. Among authors: nagasawa t. Anticancer Drugs. 2023 Aug 1;34(7):857-865. doi: 10.1097/CAD.0000000000001472. Epub 2022 Dec 5. Anticancer Drugs. 2023. PMID: 36729915 Clinical Trial.
Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Shoji T, Takatori E, Nagasawa T, Kagabu M, Baba T, Shigeto T, Matsumura Y, Shimizu D, Terada Y, Seino M, Ohta T, Nagase S, Shigeta S, Tokunaga H, Shimada M, Kaiho-Sakuma M, Furukawa S, Soeda S, Watanabe T, Takahashi F, Yokoyama Y. Shoji T, et al. Among authors: nagasawa t. Int J Clin Oncol. 2022 Dec;27(12):1874-1880. doi: 10.1007/s10147-022-02246-1. Epub 2022 Oct 10. Int J Clin Oncol. 2022. PMID: 36214925
Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).
Tanigawa T, Takeshima N, Ishikawa H, Nishio S, Usami T, Yamawaki T, Oishi T, Ihira K, Kato H, Goto M, Saito M, Taira Y, Yokoyama M, Shoji T, Kondo E, Mori A, Yokoi T, Iwasa-Inoue N, Hirashima Y, Nagasawa T, Takenaka M, Mikami M, Sugiyama T, Enomoto T. Tanigawa T, et al. Among authors: nagasawa t. Gynecol Oncol. 2022 Jun;165(3):413-419. doi: 10.1016/j.ygyno.2022.04.011. Epub 2022 Apr 27. Gynecol Oncol. 2022. PMID: 35487773 Clinical Trial.
Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma.
Egawa-Takata T, Ueda Y, Ito K, Hori K, Tadahiro S, Nagasawa T, Nishio S, Ushijima K, Koji N, Enomoto T, Kikuchi A, Honma S, Oishi T, Shimada M, Takei Y, Fujiwara H, Tanabe H, Okamoto A, Nishio Y, Yamada T, Kimura T. Egawa-Takata T, et al. Among authors: nagasawa t. Cancer Sci. 2022 May;113(5):1693-1701. doi: 10.1111/cas.15310. Epub 2022 Mar 10. Cancer Sci. 2022. PMID: 35218673 Free PMC article. Clinical Trial.
33 results